Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID‐19 Vaccine Response in People with Multiple Sclerosis
Emma Tallantyre, Nicola Vickaryous, Valerie Anderson, et al.
Annals of Neurology (2021) Vol. 91, Iss. 1, pp. 89-100
Open Access | Times Cited: 143

Showing 26-50 of 143 citing articles:

Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
Joseph J. Sabatino, Kristen Mittl, William Rowles, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 28
COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections
Dejan Jakimovski, Karen Zakalik, Samreen Awan, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 695-695
Open Access | Times Cited: 21
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis
Emma Tallantyre, Martin Scurr, Nicola Vickaryous, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 64, pp. 103937-103937
Open Access | Times Cited: 21
Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
Ana Zabalza, Georgina Arrambide, Susana Otero‐Romero, et al.
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 7, pp. 1138-1145
Closed Access | Times Cited: 20
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
Rocco Capuano, Manuela Altieri, Miriana Conte, et al.
Journal of Neurology (2022) Vol. 269, Iss. 12, pp. 6185-6192
Open Access | Times Cited: 19
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
David Baker, Eugenia Forte, Gareth Pryce, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 69, pp. 104425-104425
Open Access | Times Cited: 19
B‐cell repopulation dynamics and drug pharmacokinetics impact SARS‐CoV‐2 vaccine efficacy in anti‐CD20‐treated multiple sclerosis patients
Klara Asplund Högelin, Nicolas Ruffin, Elisa Pin, et al.
European Journal of Neurology (2022) Vol. 29, Iss. 11, pp. 3317-3328
Open Access | Times Cited: 18
Risk of MS relapse and deterioration after COVID-19: A systematic review and meta-analysis
Homa Seyedmirzaei, Dorsa Salabat, Sara KamaliZonouzi, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 83, pp. 105472-105472
Closed Access | Times Cited: 3
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
Niels J. M. Verstegen, Ruth R Hagen, Christine Kreher, et al.
Journal of Neurology Neurosurgery & Psychiatry (2024) Vol. 95, Iss. 9, pp. 855-864
Open Access | Times Cited: 3
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
David Baker, Amy MacDougall, Angray S. Kang, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 57, pp. 103448-103448
Open Access | Times Cited: 22
Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination
Maryam Golshani, Jiří Hrdý
Vaccines (2022) Vol. 10, Iss. 2, pp. 279-279
Open Access | Times Cited: 14
Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment
Christina Woopen, Marie Dunsche, Rocco Haase, et al.
Neurology Neuroimmunology & Neuroinflammation (2022) Vol. 9, Iss. 6
Open Access | Times Cited: 14
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
Aliya Jaber, Meera H. Patel, Andrew Sylvester, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 2, pp. 687-700
Open Access | Times Cited: 8
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022
Lina Jeantin, Édouard Januel, Pierre Labauge, et al.
Multiple Sclerosis Journal (2024) Vol. 30, Iss. 3, pp. 381-395
Open Access | Times Cited: 2
Development of T cell antigen-based human coronavirus vaccines against nAb-escaping SARS-CoV-2 variants
Hao Zhou, Ping Leng, Yang Wang, et al.
Science Bulletin (2024) Vol. 69, Iss. 15, pp. 2456-2470
Closed Access | Times Cited: 2
SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine
Masoud Etemadifar, Nahad Sedaghat, Hosein Nouri, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 57, pp. 103417-103417
Open Access | Times Cited: 19
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications – A pilot study
Tobias Moser, Ferdinand Otto, Ciara K. O’Sullivan, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 59, pp. 103560-103560
Open Access | Times Cited: 13
SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis
Zoé L.E. van Kempen, Eileen W Stalman, Maurice Steenhuis, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 94, Iss. 4, pp. 280-283
Closed Access | Times Cited: 13
SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
Lutz Achtnichts, А. К. Овчинников, Barbara Jakopp, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 341-341
Open Access | Times Cited: 12
Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications
Elle Levit, Erin E. Longbrake, Sharon Stoll
Multiple Sclerosis and Related Disorders (2022) Vol. 60, pp. 103719-103719
Open Access | Times Cited: 12
COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis
Yusuke Ito, Akira Honda, Mineo Kurokawa
Clinical Lymphoma Myeloma & Leukemia (2022) Vol. 22, Iss. 8, pp. e691-e707
Open Access | Times Cited: 12
Multiple sclerosis and COVID-19: A retrospective study in Iran
Behnaz Sedighi, Ali Akbar Haghdoost, Parya Jangipour Afshar, et al.
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0283538-e0283538
Open Access | Times Cited: 7
mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?
Melih Tütüncü, Serkan Demir, Gökhan Arslan, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 75, pp. 104761-104761
Open Access | Times Cited: 7
Neurologic Complications of COVID-19
Christine Gill, Tracey Cho
CONTINUUM Lifelong Learning in Neurology (2023) Vol. 29, Iss. 3, pp. 946-965
Closed Access | Times Cited: 7
Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?
David Baker, Amy MacDougall, Angray S. Kang, et al.
Clinical & Experimental Immunology (2021) Vol. 207, Iss. 3, pp. 263-271
Open Access | Times Cited: 17

Scroll to top